Stockreport

Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)

Deciphera Pharmaceuticals, Inc.  (DCPH) 
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: deciphera.com/investor-relations
PDF - Pivotal Study to Evaluate the pan-KIT and PDGFRa inhibitor, DCC-2618, in Heavily Pretreated Patients with GIST, for Whom There Are No Approved Treatmen [Read more]